oxazolidin-2-one has been researched along with Gonorrhea in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Conrad, T; Gu, K; Kankam, M; Mueller, J; Nakamura, A; Newman, LM; O'Donnell, J; Osborn, BL; Saviolakis, GA | 1 |
| Alirol, E; Bettiol, E; Delhomme, S; Gillon, JY; Luckey, A; Mueller, J; O'Brien, S; O'Donnell, J | 1 |
| Aanensen, D; Ahlstrand, J; Cole, MJ; Day, M; Golparian, D; Jacobsson, S; Sánchez-Busó, L; Unemo, M | 1 |
| Adamson, PC; Ha, SM; Klausner, JD; Lin, EY | 1 |
| Bristow, CC; Cristillo, AD; Dillon, JA; Dong, H; Grad, YH; Kirkcaldy, RD; Klausner, JD; Lawrence, K; Morris, SR; Nicholas, RA; Oldach, D; Rice, PA; Shafer, WM; Torrone, E; Wi, TE; Zhou, P | 1 |
| Batteiger, BE; Hook, EW; Johnson, SM; Kwak, H; Lawrence, K; Long, J; Marrazzo, J; Mueller, J; Seña, AC; Taylor, SN; Wierzbicki, MR | 1 |
| Fenner, A | 1 |
| Lewis, DA | 1 |
| Alm, RA; Golparian, D; Huband, M; Jacobsson, S; Jensen, JS; Mueller, J; Ohnishi, M; Unemo, M | 1 |
| Alm, RA; Barvian, K; Basarab, GS; Doig, P; Galullo, V; Gardner, H; Gowravaram, M; Huband, M; Kern, GH; Kimzey, A; Kutschke, A; Lahiri, SD; Lawrence, K; McNulty, J; Morningstar, M; Mueller, JP; Newman, JV; Perros, M; Schuck, VJ; Singh, R; Tommasi, R; Vishwanathan, K; Walkup, G | 1 |
| Alm, RA; Le, WJ; Li, S; Liu, YR; Mueller, JP; Rice, PA; Su, XH; Wan, C; Wang, BX | 1 |
| Chong, Y; Lee, H; Lee, K | 1 |
| Kirkcaldy, RD; Lawrence, K; Mueller, J; Papp, JR; Sharpe, S | 1 |
2 review(s) available for oxazolidin-2-one and Gonorrhea
| Article | Year |
|---|---|
New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.
Topics: Acenaphthenes; Anti-Bacterial Agents; Barbiturates; Drug Development; Drug Resistance, Multiple, Bacterial; Gonorrhea; Heterocyclic Compounds, 3-Ring; Humans; Isoxazoles; Macrolides; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Triazoles | 2019 |
New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Drug Resistance, Bacterial; Drug Therapy, Combination; Gonorrhea; Humans; Isoxazoles; Macrolides; Morpholines; Neisseria gonorrhoeae; Neisseriaceae Infections; Oxazolidinones; Pharyngitis; Spectinomycin; Spiro Compounds; Triazoles | 2016 |
6 trial(s) available for oxazolidin-2-one and Gonorrhea
| Article | Year |
|---|---|
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
Topics: Adult; Barbiturates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fluoroquinolones; Gonorrhea; Healthy Volunteers; Heart Rate; Humans; Isoxazoles; Long QT Syndrome; Morpholines; Oxazolidinones; Spiro Compounds | 2021 |
Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Cross-Over Studies; Gonorrhea; Healthy Volunteers; Humans; Oxazolidinones | 2023 |
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Gonorrhea; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2021 |
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bacterial Vaccines; Barbiturates; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Gonorrhea; Group Processes; Humans; Isoxazoles; Macrolides; Microbial Sensitivity Tests; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Public Health; Sexually Transmitted Diseases; Spiro Compounds; Topoisomerase Inhibitors; Triazoles; World Health Organization | 2019 |
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Barbiturates; Ceftriaxone; Female; Female Urogenital Diseases; Gonorrhea; Humans; Injections, Intramuscular; Intention to Treat Analysis; Isoxazoles; Male; Male Urogenital Diseases; Microbial Sensitivity Tests; Middle Aged; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Pharyngeal Diseases; Rectal Diseases; Sexual Partners; Spiro Compounds; Treatment Outcome; Young Adult | 2018 |
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Topics: Adult; Animals; Anti-Bacterial Agents; Barbiturates; Disease Models, Animal; DNA Topoisomerases, Type II; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gonorrhea; Haplorhini; Humans; Isoxazoles; Male; Mice; Microbial Sensitivity Tests; Middle Aged; Models, Molecular; Molecular Conformation; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Rats; Spiro Compounds; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase II Inhibitors; Young Adult | 2015 |
5 other study(ies) available for oxazolidin-2-one and Gonorrhea
| Article | Year |
|---|---|
Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Bacterial; Gonorrhea; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2021 |
Efficacy of a novel single-dose oral antibiotic for urogenital gonorrhoea.
Topics: Anti-Bacterial Agents; Barbiturates; Gonorrhea; Humans; Isoxazoles; Morpholines; Oxazolidinones; Spiro Compounds | 2019 |
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Topics: Anti-Bacterial Agents; Barbiturates; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gonorrhea; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2014 |
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gene Expression; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Tetracycline; Topoisomerase II Inhibitors; Urethritis | 2016 |
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Multiple, Bacterial; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; United States; Urethritis | 2016 |